The new care pathway for advanced pelvic cancer encourages knowledge transfer and multidisciplinary care Stockholm, Sweden – 17 October 2014 – GE Healthcare and Karolinska University Hospital in Stockholm, Sweden, have established a partnership to improve the efficiency of the care pathway for pelvic cancer patients and reduce unwarranted clinical variation. GE Healthcare will be […]
Low Level of Awareness Revealed About Breast Density and Lower Accuracy of Mammogram Screening for Dense Breasts NEW YORK, NY, October 8, 2014–A new survey entitled “Diagnosis Anxiety: The Working Mother Breast Screening Report” sheds important new information on the level of awareness women have about breast cancer today and what they are doing to […]
Important risk factor for breast cancer still not widely-known: only one out of five people globally has seen, heard or read about dense breast tissue in the last six months Countries with low awareness that dense breast tissue is an increased risk factor for developing breast cancer include UK, USA, Japan and South Korea – […]
Allegheny, PA, October 1, 2014 — Allegheny Health Network is the first center in the nation to install SenoClaire*, GE Healthcare’s (NYSE: GE) new breast tomosynthesis solution designed with a three-dimensional imaging technology. SenoClaire, which was approved by the FDA earlier this month, uses a low-dose short X-ray sweep around the positioned breast with nine […]
Aliso Viejo, CA – September 30, 2014 – GE Healthcare today announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration […]
Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone Phase III coBRIM study results will be presented today during the Presidential Symposium at the European Society of Medical Oncology (ESMO) 2014 Congress and published in the New England Journal of Medicine Roche has submitted an EU marketing authorisation application […]
Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and chemotherapy1 Median overall survival of almost five years is the longest observed to date in people […]
New Amersham™ WB system for reproducible and quantitative protein analysis The first fully-integrated system based on the traditional Western blotting technique which achieves reliably consistent results with fewer repeats and control experiments Chalfont St Giles, UK — 23 September 2014 – GE Healthcare Life Sciences (NYSE:GE) today launched Amersham WB system, a fully integrated system […]
WAUKESHA, Wis. — September 22, 2014 — GE Healthcare today announced U.S. FDA 510(k) clearance of its Discovery* IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation to help physicians deliver the best possible patient outcomes. Physicians not only want the ability to detect smaller lesions, but also the ability to determine whether […]
Data to be Presented at European Society for Medical Oncology Congress in Madrid FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 17, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, […]